SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

ALN-6222

ALNY·ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating2/10
Trial phase
unknown (no registered ClinicalTrials.gov record found; appears to be an early, minimally disclosed pipeline program)
Time to market
unknown, no clinical trial or development phase disclosed in any retrievable source
Why 2/10
No hard, dated catalyst (PDUFA, pivotal readout, or trial registration) for ALN-6222 exists in any source retrieved this session, and it appears to be an early-stage program inside a large multi-program company, so a big share-price move driven specifically by this drug in ~12 months is unlikely.
Actionable Insight NEUTRAL

ALN-6222 is real (it appears in Alnylam's Q2 2026 pipeline listing in the 8-K filed 2026-07-30) but is essentially undisclosed, no target, indication, or clinical trial could be found. Investors should not trade ALNY on this code; wait for Alnylam corporate/R&D pipeline updates (typically year-end R&D events) to disclose the program's target and phase, and treat any news as early-stage speculation. Company-level drivers (TTR franchise guidance, zilebesiran/mivelsiran readouts) are what actually move ALNY.

Price Chart

Loading chart...

Executive Summary

ALN-6222 is a development-code RNAi program at Alnylam Pharmaceuticals (Nasdaq: ALNY, ~$38B market cap per the Q2 2026 earnings analysis). This is a genuine but essentially opaque early-stage program, a tiny sliver of Alnylam's value, which is driven by its approved TTR franchise (Amvuttra) and late-stage candidates. The drug-specific rating is neutral because there is not enough public information to form a directional view; company-level sentiment is currently bearish after a Q2 earnings miss and full-year TTR guidance cut.

How It Works

Alnylam specializes in RNA-interference (RNAi) medicines, small molecules that silence disease-causing genes. ALN-6222 follows the company's "ALN-" naming convention for an investigational RNAi candidate, but its gene target, disease indication, and mechanism have not been publicly disclosed in any source retrievable this session, so nothing can be verified about how it works.

Trial Status

None found. ALN-6222 is listed among Alnylam's pipeline programs in the Q2 2026 earnings release (8-K filed 2026-07-30), alongside marketed drugs (Amvuttra, Onpattro, Givlaari, Oxlumo), late-stage candidates (nucresiran, zilebesiran, mivelsiran) and other early codes (ALN-6400, ALN-2232, ALN-5288, ALN-HTT02).

The Two-Sided Case

▲ Bull Case3
ALN-6222 is an officially listed program in Alnylam's pipeline disclosure (Q2 2026 earnings 8-K, filed 2026-07-30), confirming it is an active corporate program rather than a defunct code.
It sits on Alnylam's proven RNAi platform inside a financially strong company: Q2 2026 total revenue was $1.291B (+67% YoY) with $3.3B cash and marketable securities (per the 8-K analysis), so early pipeline programs are well funded.
The stock-level setup is contrarian: analyst consensus remains bullish (21 Buy + 8 Strong Buy, 0 Sell; mean price target $427.61 vs. ~$204 price, ~107% implied upside per the 2026-07-31 consensus snapshot), though this is company-wide and not drug-specific.
▼ Bear Case3
No public information exists on ALN-6222's target, indication, or phase, it has no ClinicalTrials.gov registration, FDA record, press release, or analyst coverage in any tool result; early-stage RNAi programs carry high preclinical attrition risk.
There is no dated catalyst for this drug within ~12 months (no PDUFA, no pivotal readout, no IND/trial registration found), so it cannot drive a scheduled binary event for ALNY.
Company-level headwinds dominate: Q2 2026 non-GAAP EPS of $1.84 missed consensus of $2.15 and FY 2026 TTR revenue guidance was cut to $4.2B-$4.5B (bearish earnings analysis, impact 7); the stock is down ~31.9% in 1 month and ~39.5% over 12 months (quant snapshot 2026-07-31), with FINRA short interest ~4.32% of estimated shares outstanding and persistently elevated daily short-volume ratios (~48-69%).

Upcoming Catalysts

  • None identified for ALN-6222 specifically in any retrieved source.
  • Watch for Alnylam corporate pipeline/R&D updates (the company typically details early programs at its year-end R&D event) where ALN-6222's target, indication, and phase may first be disclosed.
  • Company-level catalysts that actually move ALNY: Q3 2026 earnings (guidance trajectory after the cut), and readouts/progress on late-stage programs zilebesiran, nucresiran, and mivelsiran.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov